



## 期刊导读

8卷17期 2014年9月 [最新]



期刊存档

期刊存档

[查看目录](#)

## 期刊订阅



在线订阅



邮件订阅



RSS

## 作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

## 编委会

## 期刊服务



建议我们



会员服务



广告合作



继续教育

您的位置: [首页](#)>> 文章摘要

## 拜新同联合百普乐对顽固性高血压患者的降压疗效分析

龚开政, 陶金, 刘晨, 张振刚

225001 江苏省, 扬州大学第二临床医学院心血管内科

龚开政, Email: yungkzh@163.com

江苏省第四期科教兴卫工程项目基金(RC2011045); 江苏省“333”工程人才培养基金(BRA2012095)

**摘要:**目的 探讨拜新同与百普乐联合用药对顽固性高血压患者的降压疗效。方法 本研究收集于我院明确诊断为例, 回顾性分析患者的治疗用药情况, 分为拜新同(硝苯地平控释片30~60 mg/d)+百普乐(培哚普利4 mg/吲达帕胺10 mg/d)以及对照治疗组(除拜新同和百普乐以外的其他降压药物), 对比两种治疗方案的降压疗效及药物不良反应的发生率。治疗前基础血压明显升高, 但两组间并无明显差异。经过12周的治疗, 联合治疗组收缩压平均下降(25.7±13.4)mmHg, 舒张压平均下降(10.5±9.5)mmHg, 较对照治疗组降压更为明显[收缩压平均下降(14.4±10.2)mmHg, 舒张压平均下降(8.8±6.8)mmHg], 且不良反应发生率明显降低(68.0% vs. 47.1%, P<0.05)。结论 本研究结果提示, 拜新同联合百普乐可成为顽固性高血压患者的有效选择。

关键词: 高血压; 硝苯地平; 培哚普利; 治疗

[评论](#) [收藏](#) 全

文献标引: 龚开政, 陶金, 刘晨, 张振刚. 拜新同联合百普乐对顽固性高血压患者的降压疗效分析[J/CD]. 中华临床医师杂志(电子版), 2014, 8(16): 3040-3043. [复制](#)

### 参考文献:

- [1] Vongpatanasin W. Resistant Hypertension: A Review of Diagnosis and Management. *J Am Med Inf Assoc*, 2011, 18(21): 2216–2224.
- [2] Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated patients with responder, masked, false resistant, and true resistant hypertension[J]. *Hypertension*, 2005, 45(11): 1422–1428.
- [3] Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment[J]. *Hypertension*, 2008, 51(5): 1403–1414.
- [4] 孙宁玲, 霍勇, 王继光, 等. 难治性高血压诊断治疗中国专家共识[J]. 中华高血压杂志, 2013, 32(6): 1403–1414.
- [5] Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure of randomized controlled trials[J]. *Hypertension*, 2001, 38(5): 1112–1117.

[6] Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its identification and epidemiology[J]. Nat Rev Nephrol, 2013, 9(1): 51–58.

[7] Persell SD. Prevalence of resistant hypertension in the United States, 2003–2006[J]. Hypertension, 2011, 57(6): 1076–1080.

[8] Thomas F, Bean K, Pannier B, et al. Cardiovascular mortality in overweight subjects: role of associated risk factors[J]. Hypertension, 2005, 46(4): 654–659.

[9] Toal CB, Meredith PA, Elliott HL. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS[J]. Blood Press, 2012, 21 Suppl 1: 3–10.

[10] Toal CB, Meredith PA, Elliott HL. Once daily nifedipine: the formulation difference in tablet and GITS forms and its pharmacokinetic characteristics and the therapeutic responses[J]. Int J Clin Pharmacol Ther, 2006, 44(3): 202–217.

[11] Ueng KC, Ningling S, El Maksod A, et al. Efficacy and tolerability of long-acting nifedipine GITS/OROS monotherapy or combination therapy in hypertensive patients: results of a prospective, international, multicentre, observational study[J]. Clin Drug Investig, 2007, 27(6): 633–642.

[12] Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril and amlodipine in type 2 diabetes mellitus: PICASSO Trial[J]. Adv Ther, 2014, 31(3): 333–344.

[13] Sekuri C, Bayturhan O, Gocer H, et al. Effects of low-dose combination therapy with amlodipine and angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study[J]. Curr Ther Res Clin Exp, 2003, 64(9): 711–717.

[14] Farsang C, Picasso Investigators. Blood pressure and metabolic efficacy of amlodipine and amlodipine/indapamide combination in everyday practice[J]. Blood Press, 2013, 22(2): 103–108.

[15] ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens, 2013, 31(10): 1925–1938.

[16] Chobanian AV, Bakris GI. The Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003, 289(19): 2560–2571.

[17] Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic blood pressure control in combination with RAS blockade: further analysis of the 'ACTION' database in patients with hypertension[J]. J Hum Hypertens, 2011, 25(1): 63–70.

[18] Ke YN, Dong YG, Ma SP, et al. Improved blood pressure control with nifedipine GITS in combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients: results from the ADVISE study, a randomized trial[J]. Cardiovasc Ther, 2012, 30(6): 363–371.

## 短篇论著

柯萨奇病毒和人巨细胞病毒感染与1、2型糖尿病的相关性研究

温江涛，赵长新，李世宝，高云明，闻海霞，周彦..中华临床医师杂志：电子版  
2014;8(16):3044-3047.

Depmas双重血液净化治疗急性百草枯中毒的疗效观察

胡蓬勃，邱建清，许玲，丛薇，翟学伟..中华临床医师杂志：电子版  
2014;8(16):3048-3050.

后侧开窗植骨内固定在涉及后髁胫骨平台骨折中的疗效评价

张晓明，闫英杰，程战伟，冯凯，李亚会，焦雄..中华临床医师杂志：电子版  
2014;8(16):3051-3054.

白内障超声乳化吸除、硅油取出联合折叠型人工晶状体植入术治疗玻璃体切割术后硅油填充眼疗效观察

谭洪，姜兴华，杨丹，陈平..中华临床医师杂志：电子版  
2014;8(16):3055-3057.

动态心电图改良法检测老年冠心病患者心脏变时性功能

李世锋，赵峰，聂连涛，王永生，李中健..中华临床医师杂志：电子版  
2014;8(16):3058-3060.

巨大胸腺增生一例报道及文献复习

段楚骁，付圣灵，付向宁..中华临床医师杂志：电子版  
2014;8(16):3061-3065.